US FDA approves Natco Pharma's anti-cancer drug azacitidine

Natco Pharma Limited has received final approval from the US Food and Drug Administration (FDA) for azacitidine injection used in the treatment of cancer. “Natco Pharma Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US FDA for azacitidine for injection, 100 mg per vial, single-dose vial - a generic version of Vidaza by Celgene Corporation,” said the company in a press release.